Podcast
Questions and Answers
What was the primary objective of the study comparing SABA alone with SABA combined with ICS and ICS with formoterol?
What was the primary objective of the study comparing SABA alone with SABA combined with ICS and ICS with formoterol?
Which measure was used to assess asthma symptom control in the meta-analysis?
Which measure was used to assess asthma symptom control in the meta-analysis?
What did the results indicate regarding ICS-containing relievers compared to SABA alone?
What did the results indicate regarding ICS-containing relievers compared to SABA alone?
What was the risk ratio for the ICS-formoterol compared to SABA regarding severe exacerbations?
What was the risk ratio for the ICS-formoterol compared to SABA regarding severe exacerbations?
Signup and view all the answers
Which of the following was a significant finding in the indirect comparison of ICS-SABA with ICS-formoterol?
Which of the following was a significant finding in the indirect comparison of ICS-SABA with ICS-formoterol?
Signup and view all the answers
Study Notes
Asthma Reliever Therapy Comparison
-
Objective: To compare short-acting beta-agonists (SABA) alone with SABA combined with inhaled corticosteroids (ICS) and with formoterol (fast-onset, long-acting beta-agonist) combined with ICS for asthma treatment.
-
Data Sources: MEDLINE, Embase, and CENTRAL databases were searched from January 1, 2020 to September 27, 2024, including all languages.
-
Study Selection: Randomized clinical trials evaluating SABA alone, ICS with formoterol, and ICS with SABA (using combined or separate inhalers) were selected.
-
Study Population: 50,496 adult and pediatric patients; mean age, 41.0 years; 40% male.
-
Primary Outcomes:
-
Asthma symptom control (measured using a 5-item Asthma Control Questionnaire, with lower scores indicating better control, minimum important difference: 0.5 points).
-
Asthma-related quality of life (measured using an Asthma Quality of Life Questionnaire, with higher scores indicating better quality of life, minimum important difference: 0.5 points).
-
Risk of severe exacerbations.
-
Risk of serious adverse events.
-
Key Findings:
-
ICS-formoterol and ICS-SABA vs. SABA alone: Both combinations demonstrate high certainty for fewer severe exacerbations compared to SABA alone. The risk reduction was 10.3% and 4.7%, respectively, with high confidence.
-
Both combinations also show high certainty for improved asthma control compared to SABA alone. Asthma control improvements were 4.1% and 5.4% respectively.
-
ICS-formoterol vs. ICS-SABA: An indirect comparison suggests ICS-formoterol is associated with fewer severe exacerbations (5.5% risk reduction, moderate certainty) compared to ICS-SABA.
-
Serious Adverse Events: Neither ICS-formoterol nor ICS-SABA demonstrated an increased risk of serious adverse events in comparison to SABA alone, with high certainty for formoterol combination, and moderate certainty for ICS-SABA.
-
Conclusion: Inhaled corticosteroid-containing relievers (formoterol and SABA combinations) are associated with reduced asthma exacerbations, improved asthma control compared to SABA alone.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz examines the effectiveness of short-acting beta-agonists (SABA) versus SABA with inhaled corticosteroids (ICS) and formoterol. It includes data from randomized clinical trials involving adults and children to assess asthma control and quality of life. Test your knowledge on the outcomes and implications of different asthma therapies.
